Senores Pharmaceuticals Limited has informed the Exchange regarding a media release dated May 05, 2025, titled "Senores Pharmaceuticals acquires ANDA for Topiramate HCl 25,50,100 and 200 mg tablets".
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Senores Pharmaceuticals, through its US wholly-owned subsidiary, has signed an agreement to acquire the USFDA-approved ANDA for Topiramate HCl tablets (25, 50, 100 and 200 mg) from Wockhardt Limited. Topiramate is used to treat epilepsy and migraine, and the US market for the drug is approximately USD 111.47 million (MAT December 2024 as per IQVIA). The acquisition will be funded using proceeds from the company's recent IPO, in line with the objects stated in the Red Herring Prospectus. This adds to Senores' existing portfolio of 61 ANDAs and 22 CMO/CDMO commercial products for the US market.
This is a product acquisition that expands Senores' US generic portfolio in a sizeable ~USD 111 million therapeutic market, potentially adding to future US revenue. Since the deal is funded by IPO proceeds, there is no incremental debt burden, and the move is in line with the stated purpose of the IPO, which is generally viewed positively by investors.